2023
Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2018
Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatin
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia group